Under a global alliance with the Australian non-profit GC4K and Weill Cornell Medicine, PackGene aims to deliver a custom-tailored gene therapy solution for hereditary spastic paraplegia type 56, an exceptionally rare neurological disease.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Japan’s MHLW Approves Takeda’s HYQVIA Subcutaneous Injection to Treat Agammaglobulinemia or Hypogammaglobulinemia

By Feliza Mirasol

January 3rd 2025

The approval makes HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] the first and only facilitated subcutaneous immunoglobulin to be approved in Japan to treat these disorders.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Approves First Generic Version of a GLP-1 Injection for Type 2 Diabetes

By Feliza Mirasol

December 26th 2024

The approval of Hikma Pharmaceuticals’ liraglutide injection marks the first generic version of Victoza, a GLP-1 receptor agonist.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novo Nordisk Invests DKK 8.5 Billion to Build New Manufacturing Facility for Rare Disease Therapies in Denmark

By Feliza Mirasol

December 16th 2024

With the DKK 8.5 billion (US$1.2 billion) investment, Novo Nordisk will build a new modular and flexible production facility in Odense, Denmark, to produce multiple products for rare diseases.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

GSK Forms Strategic Drug Development Deals with Relation and Muna

By Feliza Mirasol

December 11th 2024

Under the deals, the parties will advance therapeutics for fibrotic diseases, osteoarthritis, and Alzheimer’s disease.

...

4 5 6 7 8

About Us

Advertise

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777